Click here for Mr. Marder's CV.
Phil Marder received his graduate training in microbiology from The Ohio State University. Upon his graduation, he joined Eli Lilly research labs as an associate cell biologist. Early in his career, Phil was given the opportunity to introduce flow cytometry as an enabling technology for Lilly’s drug discovery platforms. In this hands-on role, Phil provided his company with the powerful flow applications of immunophenotypic analysis, calcium mobilization, DNA cell cycle detection and FACS cell sorting.
During the late 1980’s, Phil began working with clinical development teams to leverage flow cytometric technology for use in drug activity biomarker studies during early clinical trials. During the late 1990’s, Phil also helped introduce the breakthrough technology of multiplexed analyte detection (Luminex) to Lilly. Phil’s vision of leveraging flow analysis to uncover pharmacodynamic effects on the surrogate target cells of blood proved to be a boon for Lilly’s drug development processes. Over the ensuing years, Phil’s research leadership developed more than a dozen of these biomarkers assays for the clinic. Phil Marder rose through the ranks at Lilly to eventually lead a group of six investigators in his role as Research Advisor. During this time, he co-authored 48 peer-reviewed scientific articles and gave podium presentations at international conferences. He is internationally recognized for his leadership in leveraging flow cytometry technology for multiple phases of pharmaceutical development. These applications include optimization of cell lines for monoclonal antibody secretion, development for cell lines neuroscience target screening, validation of primary cell assays for anti-inflammatory platforms, and most recently, detection of intracellular phosphoproteins for assaying kinase inhibitor activity of targeted cancer therapies.
Phil retired from Lilly in 2007 after more than 30 years of outstanding accomplishments including two Lilly Presidential recognitions. He has since began a consulting career and incorporated Redram Consulting, LLC in order to leverage his experience for assisting Pharma/Biotech and instrument/reagent company needs.
